Dr. Doebele is a pioneer physician-scientist and board-certified medical oncologist who lives and breathes new biology-based, tumor-agnostic strategies to offer hope. Dr. Doebele has expansive clinical and research expertise in targeted therapies and precision oncologystrategies having led research at the University of Colorado that launched the TRK field by demonstrating that that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of larotrectinib (Loxo) and entrectinib (Ignyta). Prior to joining Rain full time, Dr. Doebele was an associate professor of medicine in the division of medical oncology at the University of Colorado School of Medicine. He also served as the director of the thoracic oncology research initiative at the University of Colorado Cancer Center; and was the principal investigator of the University of Colorado Lung Cancer Specialized Program of Research Excellence. He is also a senior editor of the AACR journal, Clinical Cancer Research. Dr. Doebele received his AB in molecular biology from Princeton University, and received his MD, PhD in immunology from the University of Pennsylvania. He conducted his internal medicine residency and a medical oncology fellowship at the University of Chicago.